Free Trial
→ Top Picks for Trump’s Pro-Crypto America (From Crypto 101 Media) (Ad)

Spyre Therapeutics 5/13/2024 Earnings Report

Spyre Therapeutics logo
$21.29 -1.12 (-5.00%)
As of 04:00 PM Eastern
Earnings HistoryForecast

Spyre Therapeutics EPS Results

Actual EPS
-$1.20
Consensus EPS
-$0.90
Beat/Miss
Missed by -$0.30
One Year Ago EPS
N/A

Spyre Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spyre Therapeutics Announcement Details

Quarter
Date
5/13/2024
Time
After Market Closes

Conference Call Resources

Powered by Quartr

Spyre Therapeutics Earnings Headlines

Spyre Therapeutics (NASDAQ:SYRE) Rating Increased to Strong-Buy at The Goldman Sachs Group
February 21 at 1:35 AM | americanbankingnews.com
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $54.83
February 20 at 1:15 AM | americanbankingnews.com
Your trading day could end at 11 AM
What do you usually do between 9:35 AM and 11:00 AM? Catch up on emails? Attend a meeting? Maybe grab a coffee? For me, it's become the most important part of my trading day. 85 minutes. That's usually all it takes. Set up at 9:35 AM… Check back at 11:00 AM. And when things work out, there's an extra $100 to $150 in my account… on a $1000 starting stake. Sounds too simple, doesn't it?
February 21, 2025 | ProsperityPub (Ad)
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
February 19 at 8:00 AM | prnewswire.com
Spyre Therapeutics initiated with early-stage designation at Goldman Sachs
February 18 at 8:36 AM | markets.businessinsider.com
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call
February 10, 2025 | msn.com
See More Spyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your email.

About Spyre Therapeutics

Spyre Therapeutics (NASDAQ:SYRE), a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

View Spyre Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles